Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases.
| Title: | Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases. |
|---|---|
| Authors: | Chauhan, Aparna, Farid-Kapadia, Mufiza, Goel, Hersh, Valerio, Stephen J., Vaidya, Neel |
| Source: | Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p534-534, 132p |
| Database: | Supplemental Index |
Be the first to leave a comment!